Embryo-fetal development studies with the dietary supplement vinpocetine in the rat and rabbit

Birth Defects Research

Volumn 110, Issue 10, 2018, Pages 883-896

  Catlin, Natasha ^a,c   Waidyanatha, Suramya ^a   Mylchreest, Eve ^b,d   Miller Pinsler, Lutfiya ^b   Cunny, Helen ^a   Foster, Paul ^a   Sutherland, Vicki ^a   McIntyre, Barry ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

dietary supplements; embryo fetal development; embryotoxicity; fetal malformations; rabbit; rat; vinpocetine

Indexed keywords

APOVINCAMINIC ACID; VINPOCETINE; VINCA ALKALOID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; CONTROLLED STUDY; DIETARY SUPPLEMENT; EMBRYO DEATH; EMBRYOTOXICITY; FEMALE; FETUS MALFORMATION; FETUS RESORPTION; FETUS WEIGHT; HEART VENTRICLE SEPTUM DEFECT; LEPORIDAE; MAXIMUM CONCENTRATION; NIDATION; NONHUMAN; RAT; SPECIES DIFFERENCE; ANIMAL; DRUG EFFECT; DRUG INDUCED MALFORMATION; EMBRYO DEVELOPMENT; FETUS; FETUS DEVELOPMENT; MATERNAL EXPOSURE; PREGNANCY; PRENATAL EXPOSURE; SPRAGUE DAWLEY RAT;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; DIETARY SUPPLEMENTS; EMBRYONIC DEVELOPMENT; FEMALE; FETAL DEVELOPMENT; FETAL WEIGHT; FETUS; MATERNAL EXPOSURE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; VINCA ALKALOIDS;

EID: 85042155751     PISSN: None     EISSN: 24721727     Source Type: Journal    
DOI: 10.1002/bdr2.1207     Document Type: Article

References (64)

1. Anonymous. (1984). Cavinton, injection, tablet. Georgia Medical, 14, 363–364.
2. Armitage, P. (1971). Statistical methods in medical research (pp. 362–365). New York, NY: John Wiley and Sons.
3. Avula, B., Chittiboyina, A. G., Sagi, S., Wang, Y. H., Wang, M., Khan, I. A., & Cohen, P. A. (2016, Mar-Apr). Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States. Drug Testing and Analysis, 8(3–4), 334–343.
4. Bereczki, D., & Fekete, I. (2008). Vinpocetine for acute ischemic stroke. Cochrane Database Systematic Reviews, 1, CD000580.
5. Beyer, P. E., & Chernoff, N. (1986). The induction of supernumerary ribs in rodents: role of maternal stress. Teratogenesis, Carcinogenesis, and Mutagenesis, 6(5), 419–429.
6. Branch, S., Rogers, J. M., Brownie, C. F., & Chernoff, N. (1996). Supernumerary lumbar rib: Manifestation of basic alteration in embryonic development of ribs. Journal of Applied Toxicology, 16(2), 115–119.
7. Chernoff, N., Kavlock, R. J., Beyer, P. E., & Miller, D. (1987). The potential relationship of maternal toxicity, general stress, and fetal outcome. Teratogenesis, Carcinogenesis, and Mutagenesis, 7(3), 241–253.
8. Chernoff, N., & Rogers, J. M. (2004). Supernumerary ribs in developmental toxicity bioassays and in human populations: Incidence and biological significance. Journal of Toxicology and Environmental Health, Part B, 7(6), 437–449.
9. Chernoff, N., Rogers, J. M., Turner, C. I., & Francis, B. M. (1991). Significance of supernumerary ribs in rodent developmental toxicity studies: Postnatal persistence in rats and mice. Fundamental and Applied Toxicology, 17(3), 448–453.
10. Cholnoky, E., & Dömök, L. I. (1976). Summary of safety tests of ethyl apovincaminate. Arzneimittel Forschung (Drug Research), 26(10a), 1938–1944.
11. Clark, R. L., White, T. E. K., Clode, S. A., Gaunt, I., Winstanley, P., & Ward, S. A. (2004). Developmental toxicity of artesunate and an artenusate combination combination in the rat and rabbit. Birth Defects Research Part B Developmental and Reproductive Toxicology, 71(6), 380–394.
12. DeSesso, J. M. (1997). Comparative embryology. In R. D. Hood (Ed.), Handbook of developmental toxicology (pp. 111–174). Boca Raton: CRC Press, Inc.
13. Dixon, W. J., & Massey, F. J. (1957). Introduction to statistical analysis (2nd ed., pp. 276–278, 412). New York, NY: McGraw-Hill Book Company, Inc.
14. Du, Z. D., Roguin, N., & Wu, X. J. (1998). Spontaneous closure of muscular ventricular septal defect identified by echocardiography in neonates. Cardiology in the Young, 8(4), 500–505.
15. Dunn, O. J. (1964). Multiple comparisons using rank sums. Technometrics, 6(3), 241–252.
16. Dunnett, C. W. (1955). A multiple comparison procedure for comparing several treatments with a control. Journal of the American Statistical Association, 50(272), 1096–1121.
17. Elbary, A. A., Foda, N., El-Gazayerly, O., & El Khatib, M. (2002). Reversed phase liquid chromatographic determination of vinpocetine in human plasma and its pharmacokinetic application. Analytical Letters, 35(6), 1041–1054.
18. Feigin, V. L., Doronin, B. M., Popova, T. F., Gribatcheva, E. V., & Tchervov, D. V. (2001). Vinpocetine treatment in acute ischaemic stroke: A pilot single-blind randomized clinical trial. European Journal of Neurology, 8(1), 81–85.
19. Fleeman, T. L., Cappon, G. D., & Hurtt, M. E. (2004). Postnatal closure of membranous ventricular septal defects in Sprague-Dawley rat pups after maternal exposure with trimethadone. Birth Defects Research Part B Developmental and Reproductive Toxicology, 71(3), 185–190.
20. Foulon, O., Jaussely, C., Repetto, M., Urtizberea, M., & Blacker, A. M. (2000). Postnatal evolution of supernumerary ribs in rats after a single administration of sodium salicylate. Journal of Applied Toxicology, 20(3), 205–209.
21. Gart, J. J., Chu, K. C., & Tarone, R. E. (1979). Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. Journal of the National Cancer Institute, 62(4), 957–974.
22. Hendler, S., & Rorvik, D. (2001). Vinpocetine. In S. Hendler & D. Rorvik (Eds.), Physicians desk reference for nutritional supplements (1st ed., pp. 460–462). New Jersey: Thompson Healthcare, Medical Economics Co., Inc.
23. Hoffman, J. I. E., & Kaplan, S. (2002). The incidence of congenital heart disease. Journal of the American College of Cardiology, 39(12), 1890–1900.
24. Jeyaseelan, N., & Singh, S. (1984). Forelimb malformation in rats caused by cyclophosphamide. Acta Orthopaedica Scandinavica, 55(6), 643–646.
25. Jonckheere, A. R. (1954). A distribution-free k-sample test against ordered alternatives. Biometrika, 41(1/2), 133–145.
26. Kehra, K. S. (1981). Common fetal aberrations and their teratologic significance: A review. Fundamental and Applied Toxicology, 1, 13–18.
27. Kharshoum, R. M., Sanad, R. A., & Abdelhaleem Ali, A. M. (2013). Comparative pharmacokinetic study of two lyophilized orally disintegrating tablets formulations of vinpocetine in human volunteers. International Journal of Drug Delivery, 5(2), 167–176.
28. Kimmel, C. A., & Trammell, C. (1981). A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals. Stain Technology, 56(5), 271–273.
29. Ley, B. M. (2000). Vinpocetine: Revitalize your brain with periwinkle extract! In A health learning handbook (p. 48). Minnesota: BL Publications.
30. Li, B., Lingsma, H. F., Steyerberg, E. W., & Lesaffre, E. (2011). Logistic random effects regression models: A comparison of statistical packages for binary and ordinal outcomes. BMC Medical Research Methodology, 11, 77. https://www.amazon.com/Vinpocetine-Revitalize-Periwinkle-Learning-Handbook/dp/1890766089
31. Maconi, E., Binaghi, F., & Pitzus, F. (1986). A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Current Therapeutic Research, 40(4), 702–709.
32. Makris, S. L., Solomon, H. M., Clark, R., Shiota, K., Barbellion, S., Buschmann, J., … Wise, L. D. (2009). Terminology of developmental abnormalities in common laboratory animals (Version 2). Birth Defects Research Part B Developmental and Reproductive Toxicology, 86(4), 227–327.
33. Matalon, S. T., Ornoy, A., & Lishner, M. (2004). Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin, on the embryo and placenta). Reproductive Toxicology, 18(2), 219–230.
34. Narotsky, M. G., Francis, E. Z., & Kavlock, R. J. (1994). Developmental toxicity and structure-activity relationships of aliphatic acids, including dose-response assessment of valproic acid in mice and rats. Fundamental and Applied Toxicology, 22(2), 251–265.
35. Nie, S., Fan, X., Peng, Y., Yang, X., Wang, C., & Pan, W. (2007). In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-β-cyclodextrin. Archives of Pharmacal Research, 30(8), 991–1001.
36. Toxicology Program. DART[NTP] National &#x 2010;03: Developmental and Reproductive Toxicity Report Tables & Curves. Retrieved from https://tools.niehs.nih.gov/cebs3/views/action=main.dataReview&bin_id=2687 (Last accessed November 15, 2017).
37. Paladini, D., Palmieri, S., Lamberti, A., Teodoro, A., Martinelli, P., & Nappi, C. (2000). Characterization and natural history of ventricular septal defects in the fetus. Ultrasound in Obstetrics & Gynecology, 16(2), 118–122.
38. Pendergast, J. F., Gange, S. J., & Lindstrom, M. J. (2005). Correlated binary data. In Armitage, P., Colton, T (eds.) Encyclopedia of Biostatistics (2nd ed.), John Wiley & Sons, UK.
39. Peruzza, M., & DeJacobis, M. (1986). A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. AVD Therapy, 3(4), 201–209.
40. Ribeiro, L. S. S., Falcão, A. C., Patrício, J. A. B., Ferreira, D. C., & Veiga, F. J. B. (2007). Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavailability of vinpocetine. Journal of Pharmaceutical Sciences, 96(8), 2018–2028.
41. Rogers, J. M., Francis, B. M., Barbee, B. D., & Chernoff, N. (1991). Developmental toxicity of bromoxynil in mice and rats. Fundamental and Applied Toxicology, 17(3), 442–447.
42. Roguin, N., Du, Z. D., Barak, M., Nasser, N., Hershkowitz, S., & Milgram, E. (1995). High prevalence of muscular ventricular septal defect in neonates. Journal of American College of Cardiology, 26(6), 1545–1548.
43. Shirley, E. (1977). A non-parametric equivalent of Williams' test for contrasting increasing dose levels of treatment. Biometrics, 33(2), 386–389.
44. Sitges, M., Aldana, B. I., & Reed, R. C. (2016). Effect of the anti-depressant sertraline, the novel anti-seizure drug vinpocetine and several conventional antiepileptic drugs on the epileptiform EEG activity induced by 4-aminopyridine. Neurochemical Research, 41(6), 1365–1374.
45. Solomon, H. M., Wier, P. J., Fish, C. J., Hart, T. K., Johnson, C. M., Posobiec, L. M., … Kerns, W. D. (1997). Spontaneous and induced alterations in the cardiac membranous ventricular septum of fetal, weanling, and adult rats. Teratology, 55(3), 185–194.
46. Sozański, T., Magdalan, J., Trocha, M., Szumny, A., Merwid-Ląd, A., Słupski, W., … Szeląg, A. (2011). Omeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in rats. Pharmacological Reports, 63(5), 1258–1263.
47. Staples, R. E., & Haseman, J. K. (1974). Detection of visceral alterations in mammalian fetuses. Teratology, 9(3), 259–A38.
48. Stuckhardt, J. L., & Poppe, S. M. (1984). Fresh visceral examination of rat and rabbit fetuses used in teratogenicity testing. Teratogenesis, Carcinogenesis, and Mutagenesis, 4(2), 181–188.
49. Szatmári, S., & Whitehouse, P. (2003). Vinpocetine for cognitive impairment and dementia. Cochrane Database of Systematic Reviews, (1), CD003119. https://doi.org/10.1002/14651858.CD003119.
50. Taiji, H., & Kanzaki, J. (1986). Clinical study of vinpocetine in the treatment of vertigo. Japan Pharmacology & Therapeutics, 14(2), 577–589.
51. Thal, L. J., Salmon, D. P., Lasker, B., Bower, D., & Klauber, M. R. (1989). The safety and lack of efficacy of vinpocetine in Alzheimer's disease. Journal of American Geriatrics Society, 37(6), 515–320.
52. Thorne Research, Inc. (2002). Monograph: Vinpocetine. Alternative Medicine Review, 7(3), 240–243.
53. Truss, M. C., Stief, C. G., Ückert, S., Becker, A. J., Schultheiss, D., Machtens, S., & Jonas, U. (2000). Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World Journal of Urology, 18(6), 439–443.
54. Ujhazy, E., Preinerova, M., & Jozefik, M. (1979). Effects of cyclophosphamide on the prenatal development of the Swiss strain mice. Neoplasma, 26(5), 529–537.
55. Vereczkey, L., Szentirmay, Z., & Szporny, L. (1979). Kinetic metabolism of vinpocetine in the rat. Arzneimittel Forschung (Drug Research), 29(6), 953–956.
56. Waidyanatha, S., Troy, H., South, N., Gibbs, S., Mutlu, E., Burback, B., … Catlin, N. (2017). Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer. Toxicol Appl Pharmacol, 2018 Jan 1; 338, 83–92. https://doi.org/10.1016/j.taap.2017.11.011 [epub ahead of print]
57. Wickramaratne, G. A. S. (1988). The post-natal fate of supernumerary ribs in rat teratogenicity studies. Journal of Applied Toxicology, 8(2), 91–94.
58. Williams, D. A. (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics, 27(1), 103–117.
59. Williams, D. A. (1972). The comparison of several dose levels with a zero dose control. Biometrics, 28(2), 519–531.
60. Williams, D. A. (1986). A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control. Biometrics, 42(1), 183–186.
61. Wilson, J. G. (1965). Embryological considerations in teratology. In J. G. Wilson & J. Warkany (Eds.), Teratology: Principles and techniques (pp. 219–227). Chicago, IL: University of Chicago Press.
62. Xia, H. M., Su, L. N., Guo, J. W., Liu, G. M., Pang, Z. Q., Jiang, X. G., & Chen, J. (2010). Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 878(22), 1959–1966.
63. Xu, H., He, L., Nie, S., Guan, J., Zhang, X., Yang, X., & Pan, W. (2009). Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. Journal of Control Release, 140(1), 61–68.
64. Zorrilla, E. P. (1997). Multiparous species present problems (and possibilities) to developmentalists. Developmental Psychobiology, 30(2), 141–150.